Zobrazeno 1 - 10
of 55
pro vyhledávání: '"C. Sederholm"'
Autor:
D. Perry, C. Sederholm
Adapting Poe is a collection of essays that explores the way Edgar Allan Poe has been adapted over the last hundred years in film, comic art, music, and literary criticism. A major theme that pervades the study concerns the more recent re-imaginings
Publikováno v:
British Journal of Cancer
We report a pilot study on the Fas receptor (APO-1, CD95) in vivo in 15 human squamous cell (non-small) carcinomas and ten normal bronchial specimens. The principal aim was to investigate whether the so-called death receptor, Fas, is present in these
Autor:
Rolf A. Stahel, Karin Mattson, N. v. Walree, K. Liippo, Joachim von Pawel, Peter Drings, P. Kellokumpu-Lehtinen, Christian Manegold, W. W. ten Bokkel-Huinink, C. Sederholm, S. Ricci, Gunnar Wagenius, B. Bergman, W. Dornoff, Assad Chemaissani
Publikováno v:
Annals of Oncology. 8:525-529
Summary Background This randomised study was designed to determine the response rate, survival and toxicity of single-agent gemcitabine and cisplatin-etoposide in chemo-naive patients with locally advanced or metastatic non-small-cell lung cancer. Pa
Autor:
J, Nyman, S, Friesland, A, Hallqvist, M, Seke, S, Bergström, L, Thaning, B, Lödén, C, Sederholm, G, Wagenius
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 65(1)
A combination of chemotherapy and radiotherapy is the treatment base for locally advanced non-small cell lung cancer (NSCLC). However, both loco-regional and distant failure is frequent. Attempts to improve the loco-regional control were made in thre
Autor:
B. Bergman, Andreas Hermes, U. Aasebø, Jan Vilsvik, Sverre Sörenson, L. Ek, R. Bremnes, S. Fluge, L. Thaning, C. Sederholm, S. Sundstrøm
Publikováno v:
Pneumologie. 62
Autor:
M, Helsing, L, Thaning, C, Sederholm, K, Lamberg, J E, Martinsson, L, Ek, T, Månsson, L, Andersson, U, Hero, D, Anjedani, G, Svennson
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 24(2)
The primary aim of this phase II study was to determine the response rate of a combination of paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC) in a multicentre setting. The secondary aim was to determine time to progression (
Autor:
C, Manegold, P, Drings, J, von Pawel, S, Ricci, W, Dornoff, N, van Walree, W, ten Bokkel Huinink, A, Chemaissani, P, Stahel, B, Bergman, G, Wagenius, C, Sederholm, K, Mattson, K, Liippo, P, Kellokumpu-Lehtinen
Publikováno v:
Seminars in oncology. 24(3 Suppl 8)
This randomized, multinational, multicenter study was designed to determine the response rate of gemcitabine monotherapy and cisplatin/etoposide combination therapy in chemotherapy-naive patients with advanced, recurrent, and/or metastatic non-small
Autor:
Martin Reck, C. Caspar, R. Perng, S. Allan, Robert Pirker, M. Boyer, H. Groen, C. Sederholm, H. Riska, P. Berzinec
Publikováno v:
Journal of Clinical Oncology. 24:7190-7190
7190 Background: Erlotinib is an orally active and selective inhibitor of HER1/EGFR tyrosine kinase. In the BR.21 phase III trial, erlotinib significantly prolonged survival, delayed symptom progression, and improved quality of life in NSCLC patients
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.